Deadlines

HHS-NIH-NIAID-BAA2020-1 Research Area 002: Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis (AFM) Associated With Enterovirus D68 Supports the development of inactivated Enterovirus D68 vaccines, preferably using adjuvants that minimize regulatory concerns and expedite vaccine development into a Phase I clinical trial. Due Date: February 28, 2020, by 3 p.m. Eastern Time   Learn more

If your small business has strong experience with scientific data processing and outreach, consider sending a contract proposal to establish an Influenza Data Processing and Communication Center (iDPCC). This solicitation recompetes and renames the current influenza DPCC contract to support NIAID’s Centers of Excellence for Influenza Research and Response (CEIRR) network. Submit your proposal by April

Research Area 001: Development of Radiation/Nuclear Medical Countermeasures (MCMs) HHS-NIH-NIAID-BAA2020-1 This research topic call for proposals is part of the 2020 NIAID Omnibus Broad Agency Announcement. It supports the development of safe and effective MCMs to mitigate and/or treat tissue injuries resulting from exposure to ionizing radiation from a radiological or nuclear incident, thereby leading

HHS-NIH-NIAID-BAA2020-1 Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections, and Emerging Infectious Diseases Supports development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens and select bacterial and fungal infections identified in CDC’s report Antibiotic Resistance Threats in the United States 2019 , including optimization, preclinical

HHS-NIH-NIAID-BAA2020-1 Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases Supports development of vaccines 1) to address antibiotic resistant gram-negative bacteria focusing on but not limited to Burkholderia spp., Pseudomonas aeruginosa, Francisella tularensis, Yersinia pestis, and E. coli, and 2) for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses

HHS-NIH-NIAID-BAA2020-1 Research Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases Supports advancing the development of novel, rapid sample-to-answer candidate diagnostic products that will address biodefense and pandemic preparedness. Number of Awards/Total Costs: NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up

Innovators within the fields of pediatric oncology, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150,000 in grant funding; one year of residency at JLABS @ Washington, DC with the use of a bench, workstation, and access to the JLABS @ Washington, DC community; and mentorship from

NIH Technology Accelerator Challenge: Non-invasive Diagnostic Technologies for Global Health This challenge seeks designs for non-invasive technology platforms to diagnose sickle cell disease, malaria, and anemia. While not constrained to any specific technology, the inspiration for this challenge comes from the widespread availability of mobile phones and the potential for mobile phone-linked sensor technologies to

A Notice of Special Interest (NOSI) was issued on Feb. 6, 2020 to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV) jointly by National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of General Medical Sciences (NIGMS). Applications will be accepted on a rolling basis from February 6, 2020